Fierce Pharma July 11, 2024
Freshly equipped with two approved meds from Acorda Therapeutics, Frankfurt, Germany’s Merz Therapeutics is kicking its specialty neurology ambitions into high gear.
Wednesday, the drugmaker said it closed a $185 million deal to acquire Acorda Therapeutics’ inhaled Parkinson’s disease med Inbrija and its sustained release multiple sclerosis (MS) tablet Ampyra, which goes by the name Fampyra in certain markets.
The deal will allow the largely movement-disorder-focused company to expand its existing foothold in Parkinson’s disease and “lay an anchor” with Merz Therapeutics’ first product in MS, the company’s CEO, Stefan König, said in an interview. As part of the expansion, Merz Therapeutics plans to grow its U.S. workforce by up to 50%.
“Essentially, we want to build on our existing...
Today's Sponsors
Today's Sponsor